NIH-funded research R01 grant

Understanding ALS Risk in Workers with Certain Occupations

Official title: RFA-TS-23-001: Establishing the Cohort for Occupational Risk and Prevention Studies for Amyotrophic Lateral Sclerosis (ALS CORPS)

Funded at University of Michigan at Ann Arbor · NIH-11113782 · Data updated 2026-11-12

This project is creating a group of people at higher risk for ALS to learn how their jobs and genes might lead to the disease.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Michigan at Ann Arbor
NIH-funded
Lab location1 site (Ann Arbor, United States)
Project startSeptember 30, 2023
Project endSeptember 29, 2026
Funding year2025
Award (this year)$500,000
NIH project number5R01TS000344-03
Project IDNIH-11113782 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this effort are individuals who have a higher risk for ALS, particularly those with a history of working in production occupations or with occupational metal exposures.

Less likely to help

Patients who already have ALS or those without the specific occupational risk factors being studied may not directly benefit from this particular research.

What this research studies

Amyotrophic lateral sclerosis (ALS) is a serious condition that affects nerve cells, and we believe it comes from a mix of life experiences and genetic factors. We've noticed that people in certain production jobs and those exposed to metals at work might have a higher chance of developing ALS. This project will follow a group of individuals who are at a higher risk, especially those with specific job histories and metal exposures. By watching their health over time, we hope to understand how their environment and genes work together to cause ALS.

Why it matters

Potential benefit: If successful, this work could help identify key risk factors for ALS, leading to new strategies for preventing the disease.

How similar studies have gone: Previous case-control studies have shown a link between certain occupations and metal exposures with a higher risk of ALS, providing a foundation for this prospective cohort.

Where this research is happening

  • University of Michigan at Ann Arbor
    Ann Arbor, United States
    Active

Researchers

  • Principal investigator: Goutman, Stephen — University of Michigan at Ann Arbor
  • Study coordinator: Goutman, Stephen

Related research

Other NIH-funded projects on the same topics.

  • Investigating how DNA damage and repair mechanisms are altered in ALS and frontotemporal dementia.

    This study is looking at how problems with DNA repair might contribute to conditions like ALS and frontotemporal dementia, and it’s testing ways to fix these issues in cells from patients to help develop new treatments.

    NIH research Methodist Hospital Research Institute · Houston, United States · NIH-9980670

  • CNM-Au8 Expanded Access for ALS patients across the U.S.

    A wide-access program is testing CNM-Au8, a neuroprotective medicine, for people with ALS across all 50 states.

    NIH research New York University School of Medicine · New York, United States · NIH-11415221

  • Access to CNM-Au8 for people with ALS

    This program offers people with ALS access to CNM-Au8, an experimental oral therapy that aims to protect motor neurons and support cellular energy.

    NIH research New York University School of Medicine · New York, United States · NIH-11405390

  • Biomarker test for early ALS diagnosis using Nano-QuIC detection of misfolded TDP-43

    A new blood, spinal fluid, or nasal swab test using Nano-QuIC aims to detect misfolded TDP-43 early in people at risk for ALS to speed up diagnosis and treatment.

    NIH research University of Minnesota · Minneapolis, United States · NIH-11358045

  • Engineered regulatory immune cells to protect nerves in ALS

    Engineered regulatory immune cells (CAR Tregs) that seek out misfolded SOD1 and calm inflammation around motor neurons in people with ALS.

    NIH research Celdara Medical, LLC · Lebanon, United States · NIH-11181028

  • Using engineered immune cells to treat ALS

    This study is exploring a new way to help people with ALS by using specially designed immune cells to target harmful proteins in the body, with the hope of reducing inflammation and slowing down the disease.

    NIH research Celdara Medical, LLC · Lebanon, United States · NIH-11128419

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.